Log in

IVRO InVitro International OTC · United States

InVitro International (IVRO) news

InVitro International is a public biotech or pharmaceutical company listed on OTC under the ticker IVRO, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest InVitro International news

We have not published a story on InVitro International yet. When there is news, it will appear here.

Questions about InVitro International

What is the ticker symbol of InVitro International?

InVitro International trades under the ticker IVRO on OTC.

Where is InVitro International listed?

InVitro International is listed on OTC.

Which country or territory is InVitro International listed under?

Our directory records InVitro International under United States.

What does InVitro International do?

Our directory classifies InVitro International as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of InVitro International?

The ISIN recorded for InVitro International is US4618531036.

Does aibio.space cover InVitro International?

aibio.space lists InVitro International among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to InVitro International?

Companies in our directory listed in the same country and business area as InVitro International: Filana Therapeutics, TuHURA Biosciences, Inhibrx Biosciences, Xencor, United Therapeutics, Kalaris Therapeutics.

Investor discussion: InVitro International

Members talk about InVitro International (IVRO). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open OTC:IVRO on TradingView.

Listing details

InVitro International is a public biotech or pharmaceutical company listed on OTC under the ticker IVRO, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
InVitro International
Ticker
IVRO
Listing
OTC
Country or territory
United States
Business scope
Biotechnology
ISIN
US4618531036
Last quote in directory
2026-10-16
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.